ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2022
Clinical standards for drug-susceptible pulmonary TB.
Open access · hybridAbstract read
In one paragraph
Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Clinician and radiologist chest radiography interpretation variability in a high-TB-burden setting.IJTLD open · 2026Article
- Case Report: Nephrotic syndrome with minimal change disease during anti-tuberculosis treatment and tiopronin use.Frontiers in medicine · 2026Article
- Clinical characteristics and outcomes of tuberculosis and non-tuberculous mycobacteria infections: a population-based study of concurrent and sequential infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Analysis of gene expression in patients prior to TB treatment to identify those associated with pyrazinamide-hepatotoxicity.IJTLD open · 2025Article
- Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.Antimicrobial agents and chemotherapy · 2025Article
- Viewpoint on WHO implementation guidance on tuberculosis infection prevention and control.The European respiratory journal · 2024Article
- Perceptions and clinical practices associated with post-TB health and well-being in the Netherlands.IJTLD open · 2024Article
- Current Treatment of Drug-Resistant Tuberculosis in Children.Indian journal of pediatrics · 2024Review
- Global respiratory health priorities at the beginning of the 21st century.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Key drivers of the TB epidemic in Suriname and priority actions to reduce incidence and mortality.IJTLD open · 2024Article
- Standards for clinical trials for treating TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- TB therapeutic drug monitoring - analysis of opportunities in Romania and Ukraine.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Isoniazid and rifampicin exposure during treatment in drug-susceptible TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Lichenoid drug eruption in patients on anti-TB therapy in a high HIV prevalence setting.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Clinical standards for drug-susceptible TB in children and adolescents.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Clinical standards for the management of adverse effects during treatment for TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
47 authors at 20 institutions in 24 countries.
O W AkkermanTB Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands, Department of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
R DuarteCentro Hospitalar de Vila Nova de Gaia/Espinho; Instituto de Ciencias Biomédicas de Abel Saalazar, Universidade do Porto, Instituto de Saúde Publica da Universidade do Porto, Unidade de Investigação Clínica, ARS Norte, Porto, Portugal.
S TiberiBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, UK.
H S SchaafDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
C LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany, German Center for Infection Research (DZIF) Clinical Tuberculosis Unit, Borstel, Germany, Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany, The Global Tuberculosis Program, Texas Children´s Hospital, Immigrant and Global Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
J W C AlffenaarSydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW, Australia, School of Pharmacy, The University of Sydney Faculty of Medicine and Health, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia.
J DenholmVictorian Tuberculosis Program, Melbourne Health, Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
A C C CarvalhoLaboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, RJ, Brazil.
M S BolhuisDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
S BorisovMoscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia.
J BruchfeldDivision of Infectious Diseases, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden, Department of Infectious Disease, Karolinska University Hospital, Stockholm, Sweden.
A M CabibbeEmerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
J A CamineroDepartment of Pneumology, University General Hospital of Gran Canaria "Dr Negrin", Las Palmas, Spain, ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain.
I CarvalhoPediatric Department, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia, Portugal.
J ChakayaDepartment of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya, Department of Clinical Sciences. Liverpool School of Tropical Medicine, Liverpool, UK.
R CentisServizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
M P DalcomoReference Center Helio Fraga, FIOCRUZ, Brazil.
L D AmbrosioPublic Health Consulting Group, Lugano, Switzerland.
M DedicoatDepartment of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
K DhedaCentre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
K E DooleyCenter for Tuberculosis Research, Johns Hopkins, Baltimore, MD.
J FurinDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
J-M García-GarcíaTuberculosis Research Programme SEPAR, E-08029 Barcelona, Spain.
N A H van HestDepartment of Pulmonary Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Municipal Public Health Service Groningen, Groningen, The Netherlands.
B C de JongMycobacteriology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
X KurhasaniUBT-Higher Education Institution Prishtina, Kosovo.
A G MärtsonAntimicrobial Pharmacodynamics and Therapeutics, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
S MpagamaKilimanjaro Christian Medical University College, Moshi, United Republic of Tanzani, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania.
M Munoz TorricoClínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, México City, Mexico.
E NunesDepartment of Pulmonology of Central Hospital of Maputo, Maputo, Mozambique, Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique.
C W M OngInfectious Disease Translational Research Programme, Department of Medicine, National University of Singapore, Yong Loo Lin School of Medicine, Singapore, National University of Singapore Institute for Health Innovation & Technology (iHealthtech), Singapore, Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.
D J PalmeroFaculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
R RuslamiDepartment of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Research Center for Care and Control of Infectious Disease (RC3iD), Universitas Padjadjaran, Bandung, Indonesia.
A M I SaktiawatiDepartment of Internal Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia, Center for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
C SemutoResearch, Innovation and Data Science Division, Rwanda Biomedical Center, Kigali, Rwanda.
D R SilvaInstituto Vaccarezza, Hospital Muñiz, Buenos Aires, Argentina.
R SinglaNational Institute of Tuberculosis & Respiratory Diseases, New Delhi, India.
I SolovicNational Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ružomberok, Vyšné Hágy, Slovakia.
S SrivastavaDepartment of Pulmonary Immunology, University of Texas Health Science Centre at Tyler, Tyler, TX, USA.
J E M de SteenwinkelDepartment of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
A StoryInstitute of Epidemiology and Healthcare, University College London, London, UK, Find and Treat, University College Hospitals NHS Foundation Trust, London, UK.
M G G SturkenboomDepartment of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
M TadoliniInfectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
Z F UdwadiaP. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
A R VerhageDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
J P ZellwegerTB Competence Center, Swiss Lung Association, Berne, Switzerland.
G B MiglioriServizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
University Medical Center Groningen · NLFundação Oswaldo Cruz · BRIstituti Clinici Scientifici Maugeri · ITUniversity of Groningen · NLAzienda USL di Bologna · ITBarts Health NHS Trust · GBCatholic University in Ruzomberok · SKCentral Scientific Research Institute of Tuberculosis Russian Academy of Medical Sciences · RUCentro Hospitalar de Vila Nova de Gaia · PTEduardo Mondlane University · MZGerman Center for Infection Research · DEHarvard University · USHeartlands Hospital · GBHospital Muñiz · ARHospital Universitario de Gran Canaria Doctor Negrín · ESInstituto Nacional de Enfermedades Respiratorias · MXInstituut voor Tropische Geneeskunde · BEIstituti di Ricovero e Cura a Carattere Scientifico · ITJohns Hopkins University · USKarolinska Institutet · SE
Funding
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3MVirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4MPK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TBR01HD099756 · NICHD · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2019 to 2023
$1.6MNCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NICHD NIH HHS R01 HD099756
Abstract
PubMed holds no abstract for this paper.
Indexed as
Tuberculosis, PulmonaryAdultChildHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.